AlzeCure presents the science behind NeuroRestore and TrkA-NAM at drug development conference

AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of small molecule candidate drugs for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, today announced that the company presents the research that led to NeuroRestore and TrkA-NAM at the drug development conference ELRIG in Gothenburg, 10-12 May 2022.

The presentation, entitled The use of PathHunter cell lines to discover modulators of Trk receptors. From screen to phase 1, is given by Pontus Forsell, Head of Discovery and Research at AlzeCure Pharma, and describes the research used to develop ACD856 in the NeuroRestore platform and the TrkA-NAM project in the Painless platform.

Among other things, it describes how the compounds were developed in AlzeCure's internal research, how they affect the target mechanism in cellular studies and how these effects manifest themselves in vivo, with potent positive cognitive effects with NeuroRestore and pain-relieving effects with TrkA-NAM.

"The use of this research is a good example of how important it is to choose a cost-effective and good methodology with good translatability to effect-models in animals," said Pontus Forsell.

“The research presented shows AlzeCure's excellent capacity and is one of our foundations for being an innovative, fast and agile research and development organization with a focus on delivering important new unique therapies in both the cognitive and pain areas where there are enormous unmet medical needs", said Martin Jönsson, CEO of AlzeCure Pharma.

The presentation and abstract are available on AlzeCure’s website: (